Alice Pappani
Parma, 43122, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Discovery of a Novel Lung-Restricted ALK5 Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis.
Journal: Journal of medicinal chemistry
Published: May 19, 2026
Novel Cyclohexyl Amido Acid Antagonists of Lysophosphatidic Acid Type 1 Receptor for the Treatment of Pulmonary Fibrosis.
Journal: ACS medicinal chemistry letters
Published: November 21, 2024
Design, Synthesis, and Activity of a Novel Series of Pyridazine-Based ALK5 Inhibitors.
Journal: ACS medicinal chemistry letters
Published: July 30, 2024
Optimization of M3 Antagonist-PDE4 Inhibitor (MAPI) Dual Pharmacology Molecules for the Treatment of COPD.
Journal: Journal of medicinal chemistry
Published: August 10, 2023
Discovery of a Potent, Selective, and Orally Bioavailable Tool Compound for Probing the Role of Lysophosphatidic Acid Type 2 Receptor Antagonists in Fibrotic Disorders.
Journal: Journal of medicinal chemistry
Published: April 05, 2023
Discovery of M3 Antagonist-PDE4 Inhibitor Dual Pharmacology Molecules for the Treatment of Chronic Obstructive Pulmonary Disease.
Journal: Journal of medicinal chemistry
Published: June 18, 2021
Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.
Journal: Journal of medicinal chemistry
Published: December 05, 2017
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs.
Journal: Journal of medicinal chemistry
Published: May 11, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026